Global drugmakers are boosting U.S. manufacturing capacity as Trump administration considers tariffs on pharmaceutical imports. Companies with exposure to UK, EU, South Korea, and Japan have favorable tariff agreements. Eli Lilly plans $27 billion investment, Johnson & Johnson to raise U.S. investments by 25%, Roche to invest $50 billion, AstraZeneca to invest $50 billion, Novartis to spend $23 billion, Sanofi plans to invest at least $20 billion, Biogen to invest $2 billion, Merck to invest $1 billion, Amgen to invest $900 million, Pfizer has capacity to manage tariffs, Novo Nordisk well-positioned, AbbVie to invest $10 billion, Gilead Sciences to invest $11 billion, and Cipla expanding U.S. manufacturing.

Read more at Yahoo Finance: Factbox-Global drugmakers rush to boost US presence as tariff threat looms